Liraglutide

Fmoc-Lys(Pal-Glu-OtBu)-OH, or N2-[Fmoc]-N6-[N-(1-oxotetradecyl)-L-γ-glutamyl]-L-lysine 1′-tert-butyl ester, is a specialized ADC (antibody-drug conjugate) linker used in the synthesis of peptides. This compound combines an Fmoc (9-fluorenylmethoxycarbonyl) protecting group on the lysine side chain with a palmitoyl-glutamate (Pal-Glu) derivative at the N6 position, which imparts lipidation to the peptide. The tert-butyl ester (OtBu) group provides stability during synthesis and can be cleaved under specific conditions to reveal the bioactive form of the peptide.

Fmoc-Lys(Pal-Glu-OtBu)-OH is used primarily in the development of targeted therapies, particularly in the field of ADCs, where it serves as a versatile linker that enables the conjugation of biologically active compounds to antibodies for precise targeting and therapeutic action. The lipid modification ensures improved membrane penetration, stability, and bioavailability, making it ideal for peptide synthesis aimed at complex therapeutic applications.

CAS No: 1491158-62-3

>>Download COA

Application:

• Peptide Synthesis: Key intermediate in the synthesis of peptides with lipid-modified functional groups.
• ADC Linker: Used in the development of targeted antibody-drug conjugates for cancer therapy and other diseases.
• Pharmaceutical Research: Important in the creation of peptides for specific drug delivery applications, particularly those requiring membrane penetration and sustained action.
• Biochemical Research: Utilized in the study of peptide-modification techniques and their applications in drug development.

Packing: Customized